Novel approaches to immunotherapy for B-cell malignancies

Current Oncology Reports

Volumn 6, Issue 5, 2004, Pages 339-347

  Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19 ZL; CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; GENETIC TRANSDUCTION; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNODETECTION; IMMUNOGENICITY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; T LYMPHOCYTE; TARGET CELL; TUMOR CELL; VACCINATION;

EID: 4544245023     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0059-5     Document Type: Article

References (50)

1. Jurcic JG, Scheinberg DA: Monoclonal antibodies: leukemia and lymphoma. In Encyclopedia of Cancer, edn 2. Edited by Bertino JR. San Diego, CA: Academic Press; 2002:235-245.
2. Kwak LW, Campbell MJ, Czerwinski DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209-1215.
3. Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997, 89:3129-3135.
4. Syrengelas AD, Levy R: DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999, 162:4790-4795.
5. Timmerman JM, Levy R: Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000, 164:4797-4803.
6. Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177.
7. Dranoff G: GM-CSF-based cancer vaccines. Immunol Rev 2002, 188:147-154.
8. Kwak LW, Young HA, Pennington RW, Weeks SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996, 93:10972-10977.
9. Syrengelas AD, Chen TT, Levy R: DNA immunization induces protective immunity against B-cell lymphorna. Nat Med 1996, 2:1038-1041.
10. Timmerman JM, Singh G, Hermanson G, et al.: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002, 62:5845-5852.
11. Timmerman JM, Barrios Y, Cabrera R, et al.: Immunotherapy for lymphomas: anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Int J Hematol 2003, 77:444-455.
12. Rasmussen T, Hansson L, Osterborg A, et al.: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003, 101:4607-4610.
13. Coscia M, Mariani S, Battaglio S, et al.: Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004, 14139-145.
14. Xie X, Wacker HH, Huang S, et al.: Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res 2003, 9:167-173.
15. Niemeyer P, Tureci O, Eberle T, et al.: Expression of serologically identified tumor antigens in acute leukemias. Leuk Res 2003, 27:655-660.
16. de Rijke B, Fredrix H, Zoetbrood A, et al.: Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy. Blood 2003, 102:2885-2891.
17. Siegel S, Wagner A, Kabelitz; D, et al.: Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003, 102:4416-4423.
18. Reichardt VL, Brossart P: DC-based immunotherapy of B-cell malignancies. Cytotherapy 2004, 6:62-67.
19. Flamand V, Sornasse T, Thielemans K, et al.: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994, 24:605-610.
20. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
21. Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
22. Dabadghao S, Bergenbrant S, Anton D, et al.: Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998, 100:647-654.
23. Wen YJ, Min R, Tricot G, et al.: Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002, 99:3280-3285.
24. Lim SH, Bailey-Wood R: Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999, 83015-222.
25. Reichardt VL, Okada CY, Liso A, et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999, 93:2411-2419.
26. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000, 6:621-627.
27. Yi Q, Desikan R, Barlogie B, Munshi N: Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002, 117:297-305.
28. Yi Q: Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lymphoma 2003, 44:2031-2038.
29. Vuillier F, Maloum K, Thomas EK, et al.: Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia. Br J Haematol 2003, 120:243-250.
30. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER: Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin Exp Immunol 2001, 126:16-28.
31. Muller MR, Tsakou G, Grunebach F, et al.: Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 2004, 103:1763-1769.
32. Briones J, Timmerman JM, Panicalli DL, Levy R: Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 2003, 95:548-555.
33. Kuwashima N, Kageyama S, Eto Y, Urashima M: CD40 ligand immunotherapy in cancer: an efficient approach. Leuk Lymphoma 2001, 42:1367-1377.
34. Schultze J, Johnson P: A stimulating new target for cancer immunotherapy. Lancet 1999, 354:1225-1227.
35. Schultze JL, Cardoso AA, Freeman GJ, et al.: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A 1995, 92:8200-8204.
36. Dilloo D, Brown M, Roskrow M, et al.: CD40 ligand induces an antileukemia immune response in vivo. Blood 1997, 90:1927-1933.
37. Briones J, Timmerman J, Levy R: In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002, 62:3195-3199.
38. Kato K, Cantwell MJ, Sharma S, Kipps TJ: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998, 101:1133-1141.
39. Wierda WG, Cantwell MJ, Woods SJ, et al.: CD40-ligand (CD154) gene therapy for chronic lyraphocytic leukemia. Blood 2000, 96:2917-2924.
40. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:4008-4027.
41. Pizzoferrato E, Chu NR, Hawley TS, et al.: Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Hum Gene Ther 1997, 8:2217-2228.
42. Levitsky HI, Montgomery J, Ahmadzadeh M, et al.: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996, 156:3858-3865.
43. Porter DL, Antin JH: The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999, 50:369-386.
44. Aguilar LK, Rooney CM, Heslop HE: Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol 1999, 11:96-101.
45. Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86:2041-2050.
46. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45.
47. Brentjens RJ, Latouche JB, Santos E, et al.: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279-286.
48. Cooper LJ, Topp MS, Serrano LM, et al.: T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003, 101:1637-1644.
49. Imai C, Mihara K, Andreansky M, et al.: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
50. Jensen M, Tan G, Forman S, et al.: CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998, 4:75-83.